Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Swedish Orphan Biovitrum AB (SOBI.ST)
Solna, AB, SE
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.05% | -0.32% | +3.37% | +11.84% | +30.52% | +33.84% | +44.98% | +102.84% | +215.97% | +296.24% | +785.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | +1 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+8.5% ★ Q1'26: +11.1% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-87.8% Q1'26: +49.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+35.5% ★ Q1'26: +12.1% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+3.1% Q1'26: +26.0% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+1.8% Q1'26: +10.0% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.6% Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.07× Q1'26: 1.80× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 10 EPS Ana. |
Dec 2027 10 Rev. Ana. 10 EPS Ana. |
Dec 2028 9 Rev. Ana. 9 EPS Ana. |
Dec 2029 4 Rev. Ana. 3 EPS Ana. |
Dec 2030 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.23B
est: 3.24B (-0.5%)
|
5.20B
est: 5.19B (+0.2%)
|
6.51B
est: 6.41B (+1.6%)
|
9.14B
est: 9.08B (+0.6%)
|
14.25B
est: 14.20B (+0.3%)
|
15.26B
est: 15.09B (+1.1%)
|
15.53B
est: 15.40B (+0.8%)
|
18.79B
est: 18.42B (+2.0%)
|
22.12B
est: 23.71B (-6.7%)
|
26.03B
est: 25.91B (+0.4%)
|
28.24B
est: 28.37B (-0.5%)
|
31.93B
31.41B – 32.60B
+12.6% YoY
|
36.47B
34.64B – 38.98B
+14.2% YoY
|
40.47B
40.37B – 40.58B
+11.0% YoY
|
45.61B
44.04B – 47.72B
+12.7% YoY
|
48.38B
46.72B – 50.63B
+6.1% YoY
|
| EBITDA |
462.31M
est: 1.18B (-60.7%)
|
1.58B
est: 1.88B (-16.1%)
|
2.07B
est: 2.33B (-10.9%)
|
3.63B
est: 3.30B (+10.0%)
|
6.02B
est: 5.16B (+16.6%)
|
6.73B
est: 5.48B (+22.8%)
|
5.71B
est: 5.59B (+2.2%)
|
6.05B
est: 6.69B (-9.5%)
|
7.23B
est: 10.04B (-28.0%)
|
9.30B
est: 10.98B (-15.2%)
|
10.96B
est: 12.02B (-8.8%)
|
13.53B
13.31B – 13.81B
+12.6% YoY
|
15.45B
14.67B – 16.51B
+14.2% YoY
|
17.14B
17.10B – 17.19B
+11.0% YoY
|
19.32B
18.65B – 20.21B
+12.7% YoY
|
20.49B
19.79B – 21.44B
+6.1% YoY
|
| EBIT |
141.88M
est: 745.10M (-81.0%)
|
1.13B
est: 1.19B (-5.5%)
|
1.60B
est: 1.47B (+8.6%)
|
3.14B
est: 2.09B (+50.6%)
|
4.51B
est: 3.26B (+38.1%)
|
4.67B
est: 3.47B (+34.8%)
|
3.71B
est: 3.54B (+5.0%)
|
3.78B
est: 4.23B (-10.6%)
|
4.07B
est: 4.13B (-1.6%)
|
5.63B
est: 4.51B (+24.6%)
|
867.00M
est: 4.94B (-82.5%)
|
5.56B
5.47B – 5.68B
+12.6% YoY
|
6.35B
6.03B – 6.79B
+14.2% YoY
|
7.05B
7.03B – 7.07B
+11.0% YoY
|
7.94B
7.67B – 8.31B
+12.7% YoY
|
8.43B
8.14B – 8.82B
+6.1% YoY
|
| Net Income |
68.39M
est: 231.17M (-70.4%)
|
809.07M
est: 1.12B (-27.5%)
|
1.15B
est: 1.51B (-23.8%)
|
2.42B
est: 3.05B (-20.6%)
|
3.30B
est: 4.58B (-27.9%)
|
3.25B
est: 3.50B (-7.3%)
|
2.68B
est: 2.62B (+2.3%)
|
2.64B
est: 3.21B (-17.7%)
|
2.41B
est: 2.15B (+12.3%)
|
3.89B
est: 3.73B (+4.1%)
|
478.00M
est: 194.06M (+146.3%)
|
6.15B
5.43B – 9.30B
+3,068.9% YoY
|
7.86B
6.58B – 11.07B
+27.8% YoY
|
8.68B
7.13B – 11.80B
+10.4% YoY
|
10.10B
9.65B – 10.71B
+16.4% YoY
|
11.54B
11.03B – 12.24B
+14.3% YoY
|
| SGA |
1.35B
est: 1.27B (+5.8%)
|
1.78B
est: 2.04B (-12.8%)
|
2.10B
est: 2.52B (-16.7%)
|
2.51B
est: 3.57B (-29.6%)
|
4.94B
est: 5.58B (-11.6%)
|
5.98B
est: 5.93B (+0.9%)
|
6.29B
est: 6.05B (+4.0%)
|
7.85B
est: 7.24B (+8.5%)
|
10.16B
est: 9.33B (+8.9%)
|
7.55B
est: 10.19B (-25.9%)
|
11.14B
est: 11.16B (-0.2%)
|
12.56B
12.36B – 12.82B
+12.6% YoY
|
14.35B
13.63B – 15.34B
+14.2% YoY
|
15.92B
15.88B – 15.96B
+11.0% YoY
|
17.94B
17.33B – 18.77B
+12.7% YoY
|
19.03B
18.38B – 19.92B
+6.1% YoY
|
| EPS |
0.24
est: 0.67 (-64.1%)
|
2.99
est: 3.23 (-7.4%)
|
4.27
est: 4.36 (-2.2%)
|
8.93
est: 8.81 (+1.3%)
|
10.78
est: 13.27 (-18.7%)
|
10.52
est: 10.13 (+3.9%)
|
8.67
est: 7.58 (+14.4%)
|
8.52
est: 9.28 (-8.2%)
|
7.47
est: 6.35 (+17.6%)
|
11.37
est: 10.65 (+6.7%)
|
1.39
est: 0.55 (+150.9%)
|
18.10
15.61 – 26.75
+3,168.4% YoY
|
23.29
18.93 – 31.84
+28.6% YoY
|
26.27
20.52 – 33.93
+12.8% YoY
|
29.05
27.75 – 30.80
+10.6% YoY
|
33.21
31.73 – 35.21
+14.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 3/5 | 4/5 | 3/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi PEA MSCI Europe UCITS ETF Acc PCEU.PA | 2.37% | 9.47M | 0.15% |
| 2 | Amundi CAC 40 Daily (-2x) Inverse UCITS ETF Acc BX4.PA | 2.11% | 4.19M | 0.60% |
| 3 | iShares MSCI Sweden ETF EWD | 1.24% | 6.36M | 0.51% |
| 4 | iShares OMX Stockholm Capped UCITS ETF OM3X.DE | 1.05% | 2.25M | 0.10% |
| 5 | Touchstone Dynamic International ETF TDI | 0.84% | 628.0K | 1.19% |
| 6 | Invesco STOXX Europe 600 Optimised Health Care UCITS ETF SC0T.DE | 0.77% | 104.3K | 0.20% |
| 7 | iShares STOXX Europe Mid 200 UCITS ETF (DE) EXSD.DE | 0.63% | 4.19M | 0.20% |
| 8 | iShares STOXX Europe 600 Health Care UCITS ETF (DE) EXV4.DE | 0.60% | 4.86M | 0.46% |
| 9 | Amundi MSCI Nordic UCITS ETF - EUR (C) CN1G.DE | 0.59% | 2.11M | 0.25% |
| 10 | Xtrackers MSCI Nordic UCITS ETF 1D XDN0.L | 0.57% | 7.35M | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guido Oelkers | Chief Executive Officer & President | 29M | — |
| Henrik Stenqvist | Chief Financial Officer | 9M | male |
| Gerard Tobin | Head of Investor Relations | — | — |
| Lena Bjurner | Head of People & Communication | — | female |
| Mahmood Ladha | Head of Strategic Transformation Operations | — | male |
| Norbert Oppitz | Head of International | — | male |
| Sofiane Fahmy | Head of Europe | — | male |
| Daniel Rankin | Head of Strategy & Corporate Development | — | male |
| Torbjörn Hallberg | General Counsel & Head of Legal Affairs | — | male |
| Duane H. Barnes | Head of North America | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SOBI.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
